

Supplementary material

Stajszyk M, Kwiatkowska B, Żuber ZM, Batko B. Access to biologics and Janus kinase inhibitors for treatment of rheumatic diseases in the biosimilars era in Poland: a nation-level study. *Pol Arch Intern Med.* 2024; 134: 16655

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Figure S1 Total number of patients with RMDs (combined data for RA, PsA and axSpA) using adalimumab (ADA), etanercept (ETN), infliximab (INF), certolizumab pegol (CZP), golimumab (GOL), intravenous and subcutaneous tocilizumab (TCZ i.v., TCZ s.c.), rituximab (RTX), secukinumab (SEC), ixekizumab (IXE), tofacitinib (TOF), baricitinib (BAR) and upadacitinib (UPA) in Poland between 2016-2022.

